From the Division of Allergy, Immunology and Rheumatology, and Institute of Medicine, and Department of Health Policy and Management, and Department of Medical Management, and Department of Medical Research, Chung Shan Medical University Hospital; Graduate Institute of Integrated Medicine, China Medical University, Taichung City, Taiwan; Department of Immunology and Rheumatology, The First Affiliated Hospital of Nanchang University, Nanchang; Department of Medical Management, Chung Shan Medical University Hospital; Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China.
J.C. Wei, MD, PhD, Division of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, and Institute of Medicine, Chung Shan Medical University, and Graduate Institute of Integrated Medicine, China Medical University; L.H. Shi, MD, BD, Department of Immunology and Rheumatology, The First Affiliated Hospital of Nanchang University; J.Y. Huang, PhD, Department of Medical Research, Chung Shan Medical University Hospital; X.F. Wu, MD, PhD, Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; R. Wu, MD, PhD, Department of Immunology and Rheumatology, The First Affiliated Hospital of Nanchang University; J.Y. Chiou, PhD, Department of Health Policy and Management, Chung Shan Medical University, and Department of Medical Management, Chung Shan Medical University Hospital. J.C. Wei and L.H. Shi are co-first authors.
J Rheumatol. 2018 Mar;45(3):385-392. doi: 10.3899/jrheum.170516. Epub 2018 Jan 15.
To analyze the trend of prevalence and incidence rates for psoriatic arthritis (PsA) and psoriasis in Taiwan, and to determine the changes in medication patterns.
Data were collected from the Taiwan National Health Insurance Research Database, which covered at least 95% of the population from 2000 to 2013. International Classification of Diseases, 9th edition (ICD-9) was used to identify PsA (ICD-9 696.0) and other psoriasis (ICD-9 696.1). Medications were identified by Anatomical Therapeutic Chemical Classification code. We calculated the annual age standardized prevalence and incidence rate of PsA and psoriasis in individuals aged ≥ 16 years from 2000 to 2013, and used the Poisson regression to test the trends by Wald chi-square statistic.
The prevalence (per 100,000 population) of psoriatic diseases between 2000 and 2013 increased from 11.12 to 37.75 for PsA, and from 179.2 to 281.5 for psoriasis. The incidence (per 100,000 person-yrs) increased from 3.64 to 6.91 in PsA, while there was no significant change in psoriasis. Prevalence and incidence in PsA were more rapidly increased than in psoriasis. Sex ratio (men to women) of PsA decreased from 2.0 to 1.5 in 2000 and 2013, respectively. There was an increase in the use of disease-modifying antirheumatic drugs (DMARD), especially biologics, which is significantly different from topical therapies.
The prevalence and incidence rates of psoriatic disease, especially PsA, were increasing in Taiwan. The medication pattern showed an increase in DMARD and biologics, while use of topical therapies decreased.
分析台湾地区银屑病关节炎（PsA）和银屑病的流行率和发病率趋势，并确定药物治疗模式的变化。
数据来自于 2000 年至 2013 年涵盖至少 95%人口的台湾全民健康保险研究数据库。国际疾病分类，第 9 版（ICD-9）用于识别 PsA（ICD-9 696.0）和其他银屑病（ICD-9 696.1）。药物使用解剖治疗化学分类代码进行识别。我们计算了 2000 年至 2013 年≥16 岁人群中每 10 万人的 PsA 和银屑病的年标准化流行率和发病率，并使用泊松回归通过 Wald chi-square 统计检验趋势。
2000 年至 2013 年，银屑病疾病的患病率（每 10 万人）从 11.12 增加到 37.75 对于 PsA，从 179.2 增加到 281.5 对于银屑病。发病率（每 100,000 人-年）从 3.64 增加到 6.91 在 PsA 中，而银屑病没有明显变化。PsA 的患病率和发病率增长速度快于银屑病。PsA 的性别比（男性与女性）从 2000 年的 2.0 下降到 2013 年的 1.5。疾病修饰抗风湿药物（DMARD）的使用增加，尤其是生物制剂，与局部治疗有显著差异。
台湾地区银屑病疾病，尤其是 PsA 的患病率和发病率呈上升趋势。药物治疗模式显示 DMARD 和生物制剂的使用增加，而局部治疗的使用减少。
